SCHEMBL5082312

SCHEMBL5082312

COc1cccc(O)c1C(=O)/C=C/c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.71
KMT2A Q03164 2/20 0.71
NPSR1 Q6W5P4 2/20 0.71
MEN1 O00255 1/20 0.71
KCNA3 P22001 1/20 0.71
CYP3A4 P08684 2/20 0.69
TP53 P04637 1/20 0.69
ATM Q13315 1/20 0.69
HSD17B10 Q99714 1/20 0.69
AURKA O14965 1/20 0.65
MAOA P21397 2/20 0.63
MAOB P27338 2/20 0.63
CYP19A1 P11511 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
NFKB1 P19838 3/20 0.60
NFKB2 Q00653 3/20 0.60
RELA Q04206 3/20 0.60
ABCG2 Q9UNQ0 3/20 0.59
TNFRSF1A P19438 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5082313 1.00 MAPT (0.71) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL30383768 1.00 MAPT (0.71) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25193904 1.00 MAPT (0.71) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL977481 0.91 MAPT (0.67) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL977479 0.91 MAPT (0.67) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25201284 0.90 NFKB1 (0.69) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25193820 0.90 NFKB1 (0.69) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25191835 0.90 NFKB1 (0.69) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25265115 0.89 AURKA (0.62) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25185038 0.89 AURKA (0.62) MAPTKMT2ANPSR1MEN1KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 MAPT 4566/4885KMT2A 4362/4885NPSR1 529/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885NPSR1 4347/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 MAPT 4210/4885KMT2A 4031/4885NPSR1 255/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885NPSR1 4282/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885NPSR1 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.